Pillsbury Plant Owner Sentenced for Asbestos Violations

Federal judge Sue Myerscough sentenced a part owner of the shuttered Pillsbury Mills complex in Springfield, Illinois, Monday to three years in prison for violating clear air standards with the illegal removal of asbestos products. Joseph Chernis IV pleaded guilty to illegal removal, demolition and disposal of asbestos after using untrained workers to remove dry pipe insulation and store it in open containers, trash bags and cardboard boxes. He is still facing an ongoing civil case brought by the Illinois Environmental Protection Agency (EPA). “I have grave concerns about the damage to the community in this case,” Myerscough said during sentencing, according to The State Journal-Register. The Pillsbury Mills plant, which closed in 2001, is not far from a local high school, a park and the federal courts building in downtown Springfield. For more than a decade, the complex has been the subject of a cleanup dispute between local authorities and different ownership groups involved in salvage operations. Salvage Operation Breaking the Law The Chernis family in 2014 bought the 18-acre site, which included 20 buildings and warehouses and 30 grain silos. The original flour-milling plant opened in 1929 and became a booming Pillsbury processing and distribution factory. Unfortunately, as it expanded, the construction was done with a wide range of asbestos products, which were popular throughout much of the 20th century. The Chernis family had planned to sell off parcels o...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: asbestos exposure asbestos regulations asbestos violations asbestosis clear air standards flour-milling plant Springfield Illinois Environmental Protection Agency Joseph Chernis IV judge Sue Myerscough lung cancer mesothelioma Pillsb Source Type: news

Related Links:

Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Angiogenesis is a crucial factor in the progression of malignant pleural mesothelioma (MPM) and antiangiogenic strategies might be effective against MPM. Aminopeptidase N (APN)/CD13 promotes tumour angiogenesis and is associated with poor prognosis; however, its clinical significance in MPM remains unclear. In 37 consecutive patients with surgically resected MPM, we evaluated the association between immunohistochemical APN/CD13 expression in resected tumours and survival. Additionally, the antitumour and antiangiogenic effects of MT95-4, a fully humanised anti-APN/CD13 monoclonal antibody, were evaluated in mice orthotopic...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Original Articles: Lung cancer Source Type: research
In this issue of the European Respiratory Journal, Otsuki et al. [1] postulate that antibody targeting of aminopeptidase N (APN)/CD13 by MT95-4 might be a potential therapeutic approach for malignant pleural mesothelioma (MPM). Aminopeptidases have several functions, but their main role is breakdown of small peptides [2]. However, aminopeptidases may also play a role in angiogenesis. Angiogenesis signalling is an important hallmark of solid cancer pathophysiology in general and MPM in particular [3]. Several mechanisms are involved in this process; one of the most important factors is the shedding by the tumour of the liga...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Editorials Source Type: research
Dr. Jack West reviews his top 5 abstracts in stage I-III non-small cell lung cancer, small cell lung cancer, and mesothelioma at ASCO 2018, explaining why each is poised to change the landscape of pat... Author: BeaconMedIC Added: 05/23/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract Pemetrexed (PEM) is a novel and multi-targeted antifolate used as an antineoplastic agent for non-small cell lung cancer (NSCLC) and pleural mesothelioma. Although glucocorticoid was often used with PEM to reduce toxicity during the chemotherapy, it is not clear yet whether glucocorticoid co-administration could affect PEM efficacy in NSCLC. Here we established NSCLC cell lines and examined the effects of dexamethasone (DEX) on PEM sensitivity in vitro and in xenograft models. DEX co-administration reduced chemotherapy sensitivity to PEM in xenograft models. DEX co-administration promoted cell growth and ...
Source: Food and Chemical Toxicology - Category: Food Science Authors: Tags: Food Chem Toxicol Source Type: research
Abstract Inhalation exposure to some types of fibers (e.g., asbestos) is well known to be associated with respiratory diseases and conditions such as pleural plaques, fibrosis, asbestosis, lung cancer, and mesothelioma. In recent years, attention has expanded to other types of elongate mineral particles (EMPs) that may share similar geometry with asbestos fibers but which may differ in mineralogy. Inhalability, dimensions and orientation, and density are major determinants of the aerodynamic behavior for fibers and other EMPs; and the resultant internal dose is recognized as being the critical link between exposur...
Source: Toxicology and Applied Pharmacology - Category: Toxicology Authors: Tags: Toxicol Appl Pharmacol Source Type: research
Abstract Proteomics-based analyses are powerful means of identifying potentially useful proteins in the initial stage of drug development. Technological developments in the field of proteomics, and increases in the sensitivity of MS analyses, now facilitate identification and examination of increasingly small amounts of proteins that are differentially expressed in diseased versus normal tissues and can be candidate biomarkers or therapeutic targets. However, the current approach is for candidate proteins to be prioritized by research interest and then validated one by one; this is very inefficient. To address thi...
Source: Biological and Pharmaceutical Bulletin - Category: Drugs & Pharmacology Authors: Tags: Biol Pharm Bull Source Type: research
Dr. Samuel Epstein spent his life advocating cancer prevention and fighting against industries that put workers and consumers at risk. For more than 50 years, Epstein raised awareness of preventable causes of cancer. Among his targets was asbestos, a naturally occurring mineral linked to mesothelioma, lung cancer and other deadly conditions. He’s credited for saying the asbestos industry “successfully suppressed and manipulated information on the carcinogenicity and other hazards of asbestos.” In his 1998 book “The Politics of Cancer Revisited,” Epstein discussed the elaborate cover-up that Jo...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Publication date: Available online 30 April 2018 Source:Regulatory Toxicology and Pharmacology Author(s): Ediberto Garcia, Daniel Newfang, Jayme P. Coyle, Charles L. Blake, John W. Spencer, Leonard G. Burrelli, Giffe T. Johnson, Raymond D. Harbison Three independently conducted asbestos exposure evaluations were conducted using wire gauze pads similar to standard practice in the laboratory setting. All testing occurred in a controlled atmosphere inside an enclosed chamber simulating a laboratory setting. Separate teams consisting of a laboratory technician, or technician and assistant simulated common tasks involving wire...
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Emergency Medicine | Environmental Health | Lawsuits | Legislation | Lung Cancer | Mesothelioma | Toxicology